Phase 3 Clinical Trials With Primary Completion Dates in April 2016
This is a list of Phase 3 trials with primary completion dates in April 2016 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
|Symbol||Company||Primary Completion Date||Phase||NCT ID||Title|
|ADHD||Alcobra Ltd.||2016-04-01||Phase 3||NCT02477748||The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD|
|CBPO||China Biologic Products, Inc.||2016-04-01||Phase 3||NCT02623556||Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT6-CFP10 Allergen|
|CYAD||Celyad SA||2016-04-01||Phase 3||NCT01768702||Safety and Efficacy of Autologous Cardiopoietic Cells for Treatment of Ischemic Heart Failure.|
|CYNA||Cynapsus Therapeutics Inc.||2016-04-01||Phase 3||NCT02469090||A Phase 3 Study to Examine the Efficacy, Safety and Tolerability of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease|
|DERM||Dermira, Inc.||2016-04-01||Phase 3||NCT02346240||Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)|
|MESO||Mesoblast Limited||2016-04-01||Phase 3||NCT02336230||A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD|
|SSH||Sunshine Heart Inc||2016-04-01||Phase 3||NCT01740596||C-PulseÂ® System: A Heart Assist Device Clinical Study|